Johnson & Johnson said Tuesday it will have 20 million of the nation’s first single-dose COVID-19 vaccines available by the end of March, prompting New York City to promise door-to-door service soon for people who remain locked up. .
“The big piece we want to get to is the home vaccination of people who can’t get out of their home – that really requires the Johnson & Johnson vaccine,” Mayor Bill de Blasio told reporters.
City Health Commissioner Dave Chokshi said J & J’s testimony before a House subcommittee on vaccine development earlier in the day suggests the Big Apple could begin home vaccines next. month.
“We will be ready very quickly to carry out door-to-door home vaccinations for the elderly who enter during the month,” he said at the mayor’s information session.
“We hope that in March if everything goes according to plan with the FDA and to do so based on the supply allocated by the federal government,” said Chokshi, referring to the federal approval that still needs the J&J vaccine.
City officials have called the injection from J&J, which sought approval from the Food and Drug Administration on February 4, a game changer because it only requires a single dose and is much easier to store than their vaccines. competitors.
Johnson & Johnson Veep Dr. Richard Nettles, joining executives from coronavirus vaccine manufacturers, told members of the House Committee on Energy and Commerce Subcommittee on Oversight and Investigations that it has 4 million your injection doses ready to ship now.
“We will have 20 million doses of the vaccine available by the end of March, and we are prepared to ship 4 million doses of the vaccine immediately after emergency authorization,” Nettles said.
By the end of June, the company expects to have 100 million doses ready.
Other manufacturers also gave a summary of the total doses they hope to have available for the US.
By the end of March, Pfizer expects to have 120 million and Moderna 100 million. By the end of May, both companies expect to have 200 million and Moderna should have 300 million by the end of July.
Novavax, which has not yet been approved, has said it will have 110 million doses in total for the United States by the third quarter of the year.
And the Oxford-AstraZeneca vaccine agrees to provide a total of 300 million doses.